SCHEMBL3118472

SCHEMBL3118472

[NH]c1ncc2[nH]ncc2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 3/20 0.39
▸ HSP90AA1 P07900 1/20 0.35
▸ IDO1 P14902 1/20 0.35
▸ CDK2 P24941 1/20 0.35
▸ CHEK1 O14757 1/20 0.33
▸ MKNK1 Q9BUB5 1/20 0.32
▸ NOS1 P29475 5/20 0.31
▸ KDM4E B2RXH2 2/20 0.31
▸ MEN1 O00255 2/20 0.31
▸ MAPT P10636 2/20 0.31
▸ KMT2A Q03164 2/20 0.31
▸ METAP2 P50579 2/20 0.31
▸ PKM P14618 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ CSNK2A1 P68400 1/20 0.31
▸ ROCK2 O75116 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3117779 0.74 DYRK1A (0.39) DYRK1AHSP90AA1IDO1CDK2CHEK1
SCHEMBL4145140 0.74 KDM4E (0.44) DYRK1AHSP90AA1IDO1CDK2CHEK1
SCHEMBL23530790 0.74 ALDH1A1 (0.44) DYRK1AHSP90AA1IDO1CDK2CHEK1
SCHEMBL3105087 0.74 DYRK1A (0.36) DYRK1AHSP90AA1IDO1CDK2CHEK1
SCHEMBL3120925 0.71 DYRK1A (0.34) DYRK1AHSP90AA1IDO1CDK2MKNK1
SCHEMBL2331764 0.69 DYRK1A (0.36) DYRK1AHSP90AA1IDO1CDK2CHEK1
SCHEMBL3120521 0.69 DYRK1A (0.36) DYRK1AHSP90AA1IDO1CDK2CHEK1
SCHEMBL19211020 0.68 DYRK1A (0.35) DYRK1AHSP90AA1IDO1CDK2MKNK1
SCHEMBL8821 0.64 — —
SCHEMBL29506231 0.64 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 — — US disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 — — US disclosed
EP-1867331-A1 TRIAZOLE DERIVATIVE AND THE USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-12-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105253-A1 Triazole Derivative and Use Thereof F2R, HRH4, F2RL3 DYRK1A 1440/4885HSP90AA1 3962/4885IDO1 1000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback